Debjit Chattopadhyay

Passage Bio Inc (NASDAQ: PASG) is leveraging the UPenn Gene Therapy Program to access compelling translational research and develop a range of differentiated adeno-associated virus gene therapies for rare central nervous system disorders, according to Guggenheim. The Passage Bio Analyst:...

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouraging results from the first three patients treated with the company’s microdystrophin gene therapy program for Duchenne Muscular Dystrophy (DMD), sending the stock soaring higher by 40 percent Tuesday and prompting positive...

Jounce Therapeutics Inc (NASDAQ: JNCE) shares are tumbling Thursday in reaction to the abstract data for JTX-2011 that was made available in advance of an American Society of Clinical Oncology presentation.  JTX-2011, the company's lead product candidate, is a monoclonal antibody that...

Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...

A Wall Street Journal opinion piece suggested some eteplirsen reviewers might have escalated the conflict within the agency through a “differing-professional-opinions” (DPO) proceeding. Janney’s Debjit Chattopadhyay maintained a Neutral rating on Sarepta Therapeutics Inc (...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) spiked higher by more than 7 percent on Friday, but are still lower by nearly 35 percent year-to-date. The company reported results from a Phase 3 ACT DMD clinical trial of Translarna on Thursday. Debjit Chattopadhyay of Roth Capital maintained a...

According to ROTH Capital Partners analyst Debjit Chattopadhyay, the recent market pullback has created some excellent buying opportunities in the biotech space. During the past five years, there have been seven times that the IBB index has fallen greater than 10 percent, but it has still...

Since it hit a 52-week high on May 29, bluebird bio Inc (NASDAQ: BLUE) is more than 18 percent lower. Debjit Chattopadhyay, an analyst with Roth Capital Partners, said that given this correction, it is now time to buy the dip. Heading into the American Society of Hematology meeting in Q4, Roth...